Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

NCT02029495 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

478

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Psoriatic Arthritis

Interventions

DRUG: 210 mg brodalumab
DRUG: 140 mg brodalumab
DRUG: Placebo

Sponsor

Bausch Health Americas, Inc.